Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators.

Tracy A. Brooks(Roswell Park Comprehensive Cancer Center), Ralph J. Bernacki, Iwao Ojima(Stony Brook University), Donald J. Gruol, Maria R. Baer(University of Maryland, Baltimore), Daniel R. Kennedy(Baystate Medical Center)

PubMed

May 27, 2004

Cited by 25

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

|New England Journal of Medicine|2019|1.3k

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

|The Lancet|2021|795

<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

|Journal of Clinical Oncology|2010|764

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

|The Lancet Oncology|2017|493

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

|Journal of Clinical Oncology|2012|408